Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain

Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain

Dinutuximab (ch14.18) was the first approved monoclonal antibody against the tumor‐associated antigen disialoganglioside GD2. Despite its success in treating neuroblastoma (NB), it triggers a significant amount of neuropathic pain in patients, possibly through complement‐dependent cytotoxicity (CDC)...

Full description

Bibliographic Details
Main Authors: Xin‐Yuan Liu, Yi‐Li Chen, Guo‐Jian Liu, Xiang‐Nan Deng, Yue Cui, Jie Tan, Xing‐Chen Dong, Hua‐Ying Li, Gan‐Jun Chen, Zhi‐Min Ou, Chun‐He Wang
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:FEBS Open Bio
Subjects:
ADCC
affinity maturation
antibody engineering
anti‐GD2 antibodies
engineered Fc domain
humanized
Online Access:https://doi.org/10.1002/2211-5463.13464

Internet

https://doi.org/10.1002/2211-5463.13464

Similar Items